TopoIIb ChIP-seq in Doxorubicin-treated neonatal rat cardiomyocytes
收藏官方服务：
资源简介：
TopoIIb ChIP-seq in Doxorubicin-treated neonatal rat cardiomyocytes
应用场景：
创建时间：
2026-08-17
相关数据集
Transcriptional analysis of doxorubicin-induced cardiotoxicity
Doxorubicin (Dox) is an effective chemotherapeutic agent against a broad range of tumors. However, a threshold dose of doxorubicin causes an unacceptably high incidence of heart failure and limits it
NIAID Data Ecosystem50
m6A Demethylase ALKBH5 attenuates doxorubicin-induced cardiotoxicity via posttranscriptional stabilization of Rasal3. m6A Demethylase ALKBH5 attenuates doxorubicin-induced cardiotoxicity via posttranscriptional stabilization of Rasal3
The clinical application of anthracyclines such as doxorubicin (DOX) is limited due to their cardiotoxicity. N6-methyladenosine (m6A) plays an essential role in numerous biological processes. However,
NIAID Data Ecosystem30
The treatment for DOX-induced cardiotoxicity
The RNA-seq for the mechanism of DOX-induced cardiotoxicity
NIAID Data Ecosystem20
Targeting mitochondrial metabolism for detection and treatment of doxorubicin-induced heart failure
We conducted RNAseq using mRNA extracted from rat hearts to elucidate the effect of doxorubicin chemotherapy on the heart. Rats were 250g at the start of the treatment protocol. Tissues were collected
NIAID Data Ecosystem40
Dysregulation of intercellular communication indicates cellular processes controlled by transcription factors involved in doxorubicin-induced long-term cardiotoxicity in cancer survivors. Dysregulation of intercellular communication indicates cellular processes controlled by transcription factors involved in doxorubicin-induced long-term cardiotoxicity in cancer survivors
Long-term side effects of doxorubicin include cardiotoxicity. Because studying transcriptional network alterations in human heart at early stages of cardiac dysfunction development is not feasible, in
NIAID Data Ecosystem30
